Chronic Liver Diseases Therapeutics Global Market Report 2025

Description

Chronic liver disease therapeutics encompasses the treatments and interventions designed to manage long-term liver conditions. These therapies aim to slow disease progression, alleviate symptoms, and enhance liver function through the use of medications, lifestyle modifications, and, in some cases, advanced procedures.

The primary treatment types in chronic liver disease therapeutics include antiviral drugs, immunosuppressants, vaccines, immunoglobulins, corticosteroids, targeted therapies, and chemotherapy. Antiviral drugs are specifically formulated to inhibit the replication of viruses in the body, aiding in the treatment and management of viral infections. These therapies address a range of conditions such as hepatitis, autoimmune diseases, non-alcoholic fatty liver disease, cancer, and genetic disorders. Distribution channels for these treatments include hospital pharmacies, retail pharmacies, and online pharmacies.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The chronic liver diseases therapeutics market research report is one of a series of new reports from The Business Research Company that provides chronic liver diseases therapeutics market statistics, including the chronic liver diseases therapeutics industry global market size, regional shares, competitors with the chronic liver diseases therapeutics market share, detailed chronic liver diseases therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the chronic liver diseases therapeutics industry. This chronic liver diseases therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The chronic liver diseases therapeutics market size has grown rapidly in recent years. It will grow from $14.38 billion in 2024 to $15.88 billion in 2025 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historical period can raise the incidence of viral hepatitis, increase obesity rates, age the population, grow awareness of liver health, and increase patient access to treatment.

The chronic liver diseases therapeutics market size is expected to see rapid growth in the next few years. It will grow to $23.63 billion in 2029 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast increased focus on personalized medicine, growing the pipeline of novel therapies, expanding telemedicine and digital health solutions, and rising demand for liver disease prevention programs, as well as the rising incidence of viral hepatitis. Major trends: integration of artificial intelligence in diagnostics, biologics and gene therapies, non-invasive treatment options, combination therapies, and expansion of patient-centric care models.

The forecast of 10.5% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. gastroenterology by inflating prices of antifibrotic agents and transient elastography devices developed in Canada and South Korea, resulting in delayed cirrhosis interventions and higher hepatology department costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising consumption of alcohol is expected to drive the growth of the chronic liver disease therapeutics market. Alcohol consumption refers to the intake of ethanol-containing beverages, ranging from moderate to excessive use, which can impact health. The increase in alcohol consumption is attributed to growing social acceptance, higher incomes, and greater accessibility worldwide. Chronic liver disease therapeutics play a crucial role in managing liver damage caused by excessive alcohol intake, slowing disease progression, and enhancing liver function. For example, in June 2024, First Citizens Bank, a US financial institution, reported a 1.2% rise in direct-to-consumer (DTC) wine case sales in 2023 compared to 2022. Additionally, in December 2023, a report published by Kirin Holdings Company Limited, a Japan-based beverage company, indicated that approximately 192.1 million kiloliters of beer were consumed in 2022, marking a 2.9% increase from the previous year. As a result, the rising consumption of alcohol is contributing to the expansion of the chronic liver disease therapeutics market.

Leading companies in the chronic liver disease therapeutics sector are prioritizing the development of advanced innovations, such as RNA therapies, to address genetic and molecular mechanisms, providing more targeted and effective treatment options. RNA therapies are cutting-edge medical treatments that utilize RNA molecules to regulate gene expression or protein production, with the aim of treating or preventing diseases by targeting specific genetic mechanisms. For instance, in May 2022, Ochre Bio, a UK-based biotech company, introduced its 'Liver ICU' research facility at BioLabs@NYULangone, a biopharma incubator in New York City. This advanced facility evaluates the efficacy of next-generation RNA therapeutics using whole human livers maintained on perfusion machines. By utilizing discarded donor livers for research, the facility seeks to accelerate drug development and enhance the accuracy of liver treatment studies by replicating human physiological conditions.

In March 2024, Gilead Sciences Inc., a US-based pharmaceutical company, completed the acquisition of CymaBay Therapeutics Inc. for approximately $4.3 billion. This acquisition is intended to strengthen Gilead Sciences' portfolio in liver disease treatments, with a particular emphasis on non-alcoholic steatohepatitis (NASH) and other chronic liver conditions. CymaBay Therapeutics Inc. is a US-based company dedicated to developing therapies for liver diseases, including chronic liver conditions.

Major players in the chronic liver diseases therapeutics market are F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Novo Nordisk A/S, Dr. Reddy's Laboratories Ltd., Vir Biotechnology Inc., Alnylam Pharmaceuticals Inc., Indian Immunologicals Limited, Intercept Pharmaceuticals Inc., Viking Therapeutics Inc., Ascletis Pharma Inc., Ochre Bio Limited, Tiziana Life Sciences Ltd., Antios Therapeutics Inc.

North America was the largest region in the chronic liver diseases therapeutics market in 2024. The regions covered in chronic liver diseases therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the chronic liver diseases therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chronic liver disease therapeutics market includes revenues earned by entities by providing services such as genetic and molecular testing, liver transplantation, enzyme inhibitors, regular monitoring, and palliative and symptomatic care and related products, including pharmacological treatments, drugs, and emerging therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Chronic Liver Diseases Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on chronic liver diseases therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for chronic liver diseases therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The chronic liver diseases therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Treatment Type: Antiviral Drugs; Immunosuppressants Vaccines; Immunoglobulins; Corticosteroids; Targeted Therapy; Chemotherapy
2) By Disease Type: Hepatitis; Autoimmune Diseases; Non-Alcoholic Fatty Liver Disease; Cancer; Genetic Disorders
3) By Application: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Subsegments:
1) By Antiviral Drugs: Nucleoside Or Nucleotide Analogues; Interferons; Direct-Acting Antivirals
2) By Immunosuppressants: Calcineurin Inhibitors; mTOR Inhibitors; Purine Synthesis Inhibitors
3) By Vaccines: Hepatitis A Vaccine; Hepatitis B Vaccine; Combination Hepatitis Vaccines
4) By Immunoglobulins: Hepatitis B Immune Globulin; Intravenous Immunoglobulin
5) By Corticosteroids: Prednisolone; Methylprednisolone; Dexamethasone
6) By Targeted Therapy: Tyrosine Kinase Inhibitors; Monoclonal Antibodies
7) By Chemotherapy: Systemic Chemotherapy; Transarterial Chemoembolization Agents
Companies Mentioned: F. Hoffmann-La Roche AG; Merck & Co. Inc.; AbbVie Inc.; Bristol-Myers Squibb Company; Novartis AG; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Eli Lilly and Company; Gilead Sciences Inc.; Novo Nordisk A/S; Dr. Reddy's Laboratories Ltd.; Vir Biotechnology Inc.; Alnylam Pharmaceuticals Inc.; Indian Immunologicals Limited; Intercept Pharmaceuticals Inc.; Viking Therapeutics Inc.; Ascletis Pharma Inc.; Ochre Bio Limited; Tiziana Life Sciences Ltd.; Antios Therapeutics Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r34011u

1. Executive Summary

2. Chronic Liver Diseases Therapeutics Market Characteristics

3. Chronic Liver Diseases Therapeutics Market Trends And Strategies

4. Chronic Liver Diseases Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Chronic Liver Diseases Therapeutics Growth Analysis And Strategic Analysis Framework

5.1. Global Chronic Liver Diseases Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Chronic Liver Diseases Therapeutics Market Growth Rate Analysis
5.4. Global Chronic Liver Diseases Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Chronic Liver Diseases Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Chronic Liver Diseases Therapeutics Total Addressable Market (TAM)

6. Chronic Liver Diseases Therapeutics Market Segmentation

6.1. Global Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Antiviral Drugs
Immunosuppressants Vaccines
Immunoglobulins
Corticosteroids
Targeted Therepy
Chemotherapy
6.2. Global Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hepatitis
Autoimmune Diseases
Non-Alcoholic Fatty Liver Disease
Cancer
Genetic Disorders
6.3. Global Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
6.4. Global Chronic Liver Diseases Therapeutics Market, Sub-Segmentation Of Antiviral Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Nucleoside Or Nucleotide Analogues
Interferons
Direct-Acting Antivirals
6.5. Global Chronic Liver Diseases Therapeutics Market, Sub-Segmentation Of Immunosuppressants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Calcineurin Inhibitors
mTOR Inhibitors
Purine Synthesis Inhibitors
6.6. Global Chronic Liver Diseases Therapeutics Market, Sub-Segmentation Of Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hepatitis A Vaccine
Hepatitis B Vaccine
Combination Hepatitis Vaccines
6.7. Global Chronic Liver Diseases Therapeutics Market, Sub-Segmentation Of Immunoglobulins, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hepatitis B Immune Globulin
Intravenous Immunoglobulin
6.8. Global Chronic Liver Diseases Therapeutics Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Prednisolone
Methylprednisolone
Dexamethasone
6.9. Global Chronic Liver Diseases Therapeutics Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Tyrosine Kinase Inhibitors
Monoclonal Antibodies
6.10. Global Chronic Liver Diseases Therapeutics Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Systemic Chemotherapy
Transarterial Chemoembolization Agents

7. Chronic Liver Diseases Therapeutics Market Regional And Country Analysis

7.1. Global Chronic Liver Diseases Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Chronic Liver Diseases Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Chronic Liver Diseases Therapeutics Market

8.1. Asia-Pacific Chronic Liver Diseases Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Chronic Liver Diseases Therapeutics Market

9.1. China Chronic Liver Diseases Therapeutics Market Overview
9.2. China Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Chronic Liver Diseases Therapeutics Market

10.1. India Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Chronic Liver Diseases Therapeutics Market

11.1. Japan Chronic Liver Diseases Therapeutics Market Overview
11.2. Japan Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Chronic Liver Diseases Therapeutics Market

12.1. Australia Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Chronic Liver Diseases Therapeutics Market

13.1. Indonesia Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Chronic Liver Diseases Therapeutics Market

14.1. South Korea Chronic Liver Diseases Therapeutics Market Overview
14.2. South Korea Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Chronic Liver Diseases Therapeutics Market

15.1. Western Europe Chronic Liver Diseases Therapeutics Market Overview
15.2. Western Europe Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Chronic Liver Diseases Therapeutics Market

16.1. UK Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Chronic Liver Diseases Therapeutics Market

17.1. Germany Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Chronic Liver Diseases Therapeutics Market

18.1. France Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Chronic Liver Diseases Therapeutics Market

19.1. Italy Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Chronic Liver Diseases Therapeutics Market

20.1. Spain Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Chronic Liver Diseases Therapeutics Market

21.1. Eastern Europe Chronic Liver Diseases Therapeutics Market Overview
21.2. Eastern Europe Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Chronic Liver Diseases Therapeutics Market

22.1. Russia Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Chronic Liver Diseases Therapeutics Market

23.1. North America Chronic Liver Diseases Therapeutics Market Overview
23.2. North America Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Chronic Liver Diseases Therapeutics Market

24.1. USA Chronic Liver Diseases Therapeutics Market Overview
24.2. USA Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Chronic Liver Diseases Therapeutics Market

25.1. Canada Chronic Liver Diseases Therapeutics Market Overview
25.2. Canada Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Chronic Liver Diseases Therapeutics Market

26.1. South America Chronic Liver Diseases Therapeutics Market Overview
26.2. South America Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Chronic Liver Diseases Therapeutics Market

27.1. Brazil Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Chronic Liver Diseases Therapeutics Market

28.1. Middle East Chronic Liver Diseases Therapeutics Market Overview
28.2. Middle East Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Chronic Liver Diseases Therapeutics Market

29.1. Africa Chronic Liver Diseases Therapeutics Market Overview
29.2. Africa Chronic Liver Diseases Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Chronic Liver Diseases Therapeutics Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Chronic Liver Diseases Therapeutics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Chronic Liver Diseases Therapeutics Market Competitive Landscape And Company Profiles

30.1. Chronic Liver Diseases Therapeutics Market Competitive Landscape
30.2. Chronic Liver Diseases Therapeutics Market Company Profiles
- 30.2.1. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Chronic Liver Diseases Therapeutics Market Other Major And Innovative Companies

31.1. GlaxoSmithKline plc
31.2. Takeda Pharmaceutical Company Limited
31.3. Eli Lilly and Company
31.4. Gilead Sciences Inc.
31.5. Novo Nordisk A/S
31.6. Dr. Reddy's Laboratories Ltd.
31.7. Vir Biotechnology Inc.
31.8. Alnylam Pharmaceuticals Inc.
31.9. Indian Immunologicals Limited
31.10. Intercept Pharmaceuticals Inc.
31.11. Viking Therapeutics Inc.
31.12. Ascletis Pharma Inc.
31.13. Ochre Bio Limited
31.14. Tiziana Life Sciences Ltd.
31.15. Antios Therapeutics Inc.

32. Global Chronic Liver Diseases Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Chronic Liver Diseases Therapeutics Market

34. Recent Developments In The Chronic Liver Diseases Therapeutics Market

35. Chronic Liver Diseases Therapeutics Market High Potential Countries, Segments and Strategies

35.1 Chronic Liver Diseases Therapeutics Market In 2029 - Countries Offering Most New Opportunities
35.2 Chronic Liver Diseases Therapeutics Market In 2029 - Segments Offering Most New Opportunities
35.3 Chronic Liver Diseases Therapeutics Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer